| Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell–and patient-derived tumor organoids L Huang, A Holtzinger, I Jagan, M BeGora, I Lohse, N Ngai, C Nostro, ... Nature medicine 21 (11), 1364-1371, 2015 | 771 | 2015 |
| Durvalumab with or without tremelimumab for patients with metastatic pancreatic ductal adenocarcinoma: a phase 2 randomized clinical trial EM O’Reilly, DY Oh, N Dhani, DJ Renouf, MA Lee, W Sun, G Fisher, ... JAMA oncology 5 (10), 1431-1438, 2019 | 576 | 2019 |
| Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution M Chan-Seng-Yue, JC Kim, GW Wilson, K Ng, EF Figueroa, GM O’Kane, ... Nature genetics 52 (2), 231-240, 2020 | 521 | 2020 |
| Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, ... Cancer discovery 10 (1), 40-53, 2020 | 276 | 2020 |
| A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors PC McDonald, S Chia, PL Bedard, Q Chu, M Lyle, L Tang, M Singh, ... American journal of clinical oncology 43 (7), 484-490, 2020 | 196 | 2020 |
| Regulation of pH by carbonic anhydrase 9 mediates survival of pancreatic cancer cells with activated KRAS in response to hypoxia PC McDonald, SC Chafe, WS Brown, S Saberi, M Swayampakula, ... Gastroenterology 157 (3), 823-837, 2019 | 188 | 2019 |
| Homologous recombination deficiency and platinum-based therapy outcomes in advanced breast cancer EY Zhao, Y Shen, E Pleasance, K Kasaian, S Leelakumari, M Jones, ... Clinical Cancer Research 23 (24), 7521-7530, 2017 | 184 | 2017 |
| Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial T Conroy, F Castan, A Lopez, A Turpin, MB Abdelghani, AC Wei, E Mitry, ... JAMA oncology 8 (11), 1571-1578, 2022 | 182 | 2022 |
| Nonsmall cell lung carcinoma with neuroendocrine differentiation—an entity of no clinical or prognostic significance DN Ionescu, D Treaba, CB Gilks, S Leung, D Renouf, J Laskin, ... The American journal of surgical pathology 31 (1), 26-32, 2007 | 178 | 2007 |
| Adjuvant chemotherapy use and outcomes of patients with high‐risk versus low‐risk stage II colon cancer A Kumar, HF Kennecke, DJ Renouf, HJ Lim, S Gill, R Woods, C Speers, ... Cancer 121 (4), 527-534, 2015 | 170 | 2015 |
| Altered gene expression along the glycolysis–cholesterol synthesis axis is associated with outcome in pancreatic cancer JM Karasinska, JT Topham, SE Kalloger, GH Jang, RE Denroche, ... Clinical Cancer Research 26 (1), 135-146, 2020 | 162 | 2020 |
| NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma MR Jones, LM Williamson, JT Topham, MKC Lee, A Goytain, J Ho, ... Clinical Cancer Research 25 (15), 4674-4681, 2019 | 154 | 2019 |
| Ocular toxicity of targeted therapies DJ Renouf, JP Velazquez-Martin, R Simpson, LL Siu, PL Bedard Journal of Clinical Oncology 30 (26), 3277-3286, 2012 | 142 | 2012 |
| Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ... Nature Cancer 1 (4), 452-468, 2020 | 139 | 2020 |
| Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer RDA Peixoto, C Speers, CE McGahan, DJ Renouf, DF Schaeffer, ... Cancer medicine 4 (8), 1171-1177, 2015 | 139 | 2015 |
| Lessons learned from the application of whole-genome analysis to the treatment of patients with advanced cancers J Laskin, S Jones, S Aparicio, S Chia, C Ch'ng, R Deyell, P Eirew, A Fok, ... Molecular Case Studies 1 (1), a000570, 2015 | 131 | 2015 |
| Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer MR Jones, H Lim, Y Shen, E Pleasance, C Ch'ng, C Reisle, ... Annals of Oncology 28 (12), 3092-3097, 2017 | 114 | 2017 |
| Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma T Golan, GM O’Kane, RE Denroche, M Raitses-Gurevich, RC Grant, ... Gastroenterology 160 (6), 2119-2132. e9, 2021 | 111 | 2021 |
| Tumor budding is an independent adverse prognostic factor in pancreatic ductal adenocarcinoma K O’Connor, HH Li-Chang, SE Kalloger, RD Peixoto, DL Webber, ... The American journal of surgical pathology 39 (4), 472-478, 2015 | 104 | 2015 |
| Genome-wide synthetic lethal screen unveils novel CAIX-NFS1/xCT axis as a targetable vulnerability in hypoxic solid tumors SC Chafe, FS Vizeacoumar, G Venkateswaran, O Nemirovsky, S Awrey, ... Science advances 7 (35), eabj0364, 2021 | 101 | 2021 |
